Balyasny Asset Management
NKTR icon

Balyasny Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Balyasny Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,667
Closed -$10.8M – 1630
2018
Q3 		$10.8M Buy
+12,667
New +$10.8M 0.05% 465
2018
Q2 		– Sell
-2,620
Closed -$4.18M – 2031
2018
Q1 		$4.18M Buy
+2,620
New +$3.38M 0.02% 764

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's NKTR Position: Q2 2026 in Review

Balyasny Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 35,851 shares — an estimated $2.58M sold.

Balyasny Asset Management first reported a position in NKTR in Q2 2015 and held it in 26 quarters. The position peaked at $19M in Q3 2017. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Balyasny Asset Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 35,851 Nektar Therapeutics shares in Q2 2026, an estimated $2.58M.
  • Balyasny Asset Management first reported a position in Nektar Therapeutics in Q2 2015 and held it in 26 quarters.
  • Balyasny Asset Management's Nektar Therapeutics position peaked at $19M in Q3 2017.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.